242 related articles for article (PubMed ID: 33048309)
1. Reactor produced [
Chakravarty R; Shetty P; Nair KVV; Rajeswari A; Jagadeesan KC; Sarma HD; Rangarajan V; Krishnatry R; Chakraborty S
Ann Nucl Med; 2020 Dec; 34(12):899-910. PubMed ID: 33048309
[TBL] [Abstract][Full Text] [Related]
2.
Nelson BJB; Leier S; Wilson J; Wuest M; Doupe J; Andersson JD; Wuest F
Nucl Med Biol; 2024; 128-129():108875. PubMed ID: 38199184
[TBL] [Abstract][Full Text] [Related]
3. Establishing Reliable Cu-64 Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging.
Xie Q; Zhu H; Wang F; Meng X; Ren Q; Xia C; Yang Z
Molecules; 2017 Apr; 22(4):. PubMed ID: 28420176
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of the therapeutic application of a mixture of
De Nardo L; Pupillo G; Mou L; Esposito J; Rosato A; Meléndez-Alafort L
Med Phys; 2022 Apr; 49(4):2709-2724. PubMed ID: 35134261
[TBL] [Abstract][Full Text] [Related]
5. A simple and robust method for radiochemical separation of no-carrier-added
Chakravarty R; Rajeswari A; Shetty P; Jagadeesan KC; Ram R; Jadhav S; Sarma HD; Dash A; Chakraborty S
Appl Radiat Isot; 2020 Nov; 165():109341. PubMed ID: 32745917
[TBL] [Abstract][Full Text] [Related]
6. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.
Cai H; Wu JS; Muzik O; Hsieh JT; Lee RJ; Peng F
J Nucl Med; 2014 Apr; 55(4):622-8. PubMed ID: 24639459
[TBL] [Abstract][Full Text] [Related]
7. Fast and cost-effective cyclotron production of
do Carmo SJC; Alves VHP; Alves F; Abrunhosa AJ
Dalton Trans; 2017 Oct; 46(42):14556-14560. PubMed ID: 28702664
[TBL] [Abstract][Full Text] [Related]
8. Theranostics of malignant melanoma with 64CuCl2.
Qin C; Liu H; Chen K; Hu X; Ma X; Lan X; Zhang Y; Cheng Z
J Nucl Med; 2014 May; 55(5):812-7. PubMed ID: 24627435
[TBL] [Abstract][Full Text] [Related]
9. Intrinsically radioactive [64Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence.
Guo W; Sun X; Jacobson O; Yan X; Min K; Srivatsan A; Niu G; Kiesewetter DO; Chang J; Chen X
ACS Nano; 2015 Jan; 9(1):488-95. PubMed ID: 25549258
[TBL] [Abstract][Full Text] [Related]
10. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
11. PET imaging analysis with 64Cu in disulfiram treatment for aberrant copper biodistribution in Menkes disease mouse model.
Nomura S; Nozaki S; Hamazaki T; Takeda T; Ninomiya E; Kudo S; Hayashinaka E; Wada Y; Hiroki T; Fujisawa C; Kodama H; Shintaku H; Watanabe Y
J Nucl Med; 2014 May; 55(5):845-51. PubMed ID: 24627433
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
13. Copper-64: a real theranostic agent.
Gutfilen B; Souza SA; Valentini G
Drug Des Devel Ther; 2018; 12():3235-3245. PubMed ID: 30323557
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution in rats and estimates of doses to humans from (64)CuCl2, a potential theranostic tracer.
Manrique-Arias JC; Carrasco-Hernández J; Reyes PG; Ávila-Rodríguez MA
Appl Radiat Isot; 2016 Sep; 115():18-22. PubMed ID: 27295514
[TBL] [Abstract][Full Text] [Related]
15. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
Shokeen M; Anderson CJ
Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and formulation of [
Green MA; Mathias CJ
Appl Radiat Isot; 2022 Apr; 182():110119. PubMed ID: 35093818
[TBL] [Abstract][Full Text] [Related]
19. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design?
Singh AN; Dakanali M; Hao G; Ramezani S; Kumar A; Sun X
Eur J Med Chem; 2014 Jun; 80():308-15. PubMed ID: 24793881
[TBL] [Abstract][Full Text] [Related]
20. Preclinical PET imaging study of lung cancer with
Wang Q; Song D; Ma X; Wu X; Jiang L
Ann Nucl Med; 2020 Sep; 34(9):653-662. PubMed ID: 32567008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
